Latest Healthcare News

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.

Regis Healthcare reported robust FY25 financial results, driven by increased occupancy, strategic acquisitions, and a strong balance sheet, positioning itself well ahead of the new Aged Care Act reforms.

Regis Healthcare has reported a robust FY25 financial performance, marked by significant profit growth and strategic acquisitions, positioning itself for ambitious expansion in Australia’s aged care sector.

Regis Healthcare delivered a robust FY25 performance with a 14.5% revenue increase and a dramatic turnaround to a $49 million net profit. The company is advancing growth through acquisitions and greenfield developments, positioning itself strongly ahead of upcoming sector reforms.

Vitura Health Limited has announced its third fully franked dividend of 0.2 cents per share following a profitable FY2025, reinforcing its unique position in the medicinal cannabis sector. Shareholders are invited to participate in a discounted Dividend Reinvestment Plan.

Vitura Health reported modest revenue growth but a robust 23.5% increase in EBITDA for FY2025, fueled by key acquisitions and expanding telehealth services. Despite margin pressures in medicinal cannabis, the company’s strategic reset under new leadership sets the stage for further growth.

Apiam Animal Health has entered a Process Deed granting Adamantem exclusivity to pursue a $0.88 per share acquisition proposal. The Independent Board Committee signals intent to recommend the deal, pending due diligence and shareholder approval.

Vitura Health reported a modest revenue increase to $124 million for FY2025, while net profit dipped 5.35% due to margin pressures and investment in new platforms. The company declared a fully franked dividend and highlighted growth in telehealth and medical services.

Navigator Global Investments (NGI) reported a strong FY25 with record earnings driven by robust revenue growth and strategic investments, reinforcing its unique position in alternative asset management on the ASX.

Navigator Global Investments has delivered a record financial performance in FY25, with Adjusted EBITDA rising 26% and net profit after tax soaring 80%, underpinned by strong asset growth and strategic board changes.

Navigator Global Investments Limited (ASX, NGI) reported a robust 80% increase in net profit for FY25, driven by strong performance fees and strategic acquisitions including 1315 Capital Partners. The company also announced key board transitions as it reviews its dividend policy amid growth ambitions.

PeopleIN’s FY2025 results reveal a revenue dip amid challenging conditions, offset by strategic cost savings, strong cash flow, and a $6 million share buy-back, positioning the company for growth in Queensland and Defence sectors.